Calendario›IMUX›IMU-838
IMU-838
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Ensayo de IMMUNIC, INC. en COVID-19.
Más ensayos de: COVID-19.
- Fase
- Fase 2/3
- Estado
- Completado
- Participantes
- 234
- Centros
- 4
- Fin del objetivo primario
- ene 2021
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, doble ciego. Comenzó en jun 2020.
Qué mide
Proporcion de pacientes sin ninguna necesidad de INV hasta EoS (Throughout the Study (Day 0 to Day 28)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroAt present there is no approved drug treatment for Covid-19. In this study we plan to investigate if an experimental drug called IMU-838 (vidofludimus calcium) can improve your symptoms, prevent worsening that would initiate further treatments such as ventilation, and can lower your virus number if given in addition to your doctor's choice of standard therapy. We will also test if IMU-838 has any side effects and measure the level of IMU 838 in your blood. Experimental drug means that it is not yet authorized for marketing in your country. To date approximately 600 individuals have received IMU-838 (or a drug similar to IMU-838 that contains the same active substance as IMU-838) in research studies.
Más ensayos de IMUX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| IMU-838 · EMPhASIS | Fase 2 | En marcha, sin reclutar | abr 2020 (real) |
| IMU-838 tablets · ENSURE-2 | Fase 3 | En marcha, sin reclutar | nov 2026 (prevista) |
| IMU-838 tablets · ENSURE-1 | Fase 3 | En marcha, sin reclutar | nov 2026 (prevista) |
| IMU-838 · CALLIPER | Fase 2 | Sin noticias del promotor | ene 2025 (prevista, ya pasada: sin actualizar en el registro) |
| IMU-935 | Fase 1 | Interrumpido | may 2023 (real) |
| IMU-838 · CALDOSE-1 | Fase 2 | Interrumpido | nov 2022 (real) |
Todos los de IMUX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04379271), actualizada en oct 2024.